trial
as of 2026-07-01Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
NCTId NCT06740383
at a glance
Phase — · Recruiting
Enrollment 320 (estimated)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2027-06-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Recruiting
Enrollment
320 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2023-01-01
Primary completion
2027-06-30
Eligibility
ALL · 18 Years · 40 Years
Interventions & indications
Drugs
—
Indications
Sponsors
Beth Israel Deaconess Medical CenterLead Sponsor
University of ChicagoCollaborator
University of Texas Southwestern Medical CenterCollaborator
Yale UniversityCollaborator
Hartford HospitalCollaborator
University of GeorgiaCollaborator
Mclean HospitalCollaborator
National Institute of Mental Health (NIMH)Collaborator
Investigators
1
Matcheri S. Keshavan, MDPrincipal Investigator
Sites
6 total
Hartford, United StatesAthens, United StatesChicago, United StatesBelmont, United StatesBoston, United StatesDallas, United States
Facts & assertions
4 sourced
Enrollment
320
Phase
NA
Primary Completion Date
2027-06-30
Status
RECRUITING
relationships
The graph out of here
lead_sponsor
collaborator
indication
investigator
person